Sanofi/Regeneron prevail in Euro patent dispute with Amgen on cholesterol drugs

• The European Patent Office (EPO) has ruled in favor of Sanofi (SNY -1.1%) and Regeneron Pharmaceuticals (REGN -1.2%) invalidating certain claims of a patent held by competitor Amgen (AMGN -0.3%) covering PCSK9 inhibitor Repatha (evolocumab) relevant to Praluent (alirocumab).
• Praluent will continue to be available in European countries where it is approved.
• In August 2019, a U.S. court found that certain claims of Amgen's patent for antibodies targeting PCSK9 were invalid based on lack of enablement (in patent law lack of enablement means that the filed application would not have been sufficient to teach a skilled person how to make and/or use the full scope of the claimed invention without undue experimentation).
• https://seekingalpha.com/news/3628348-sanofi-regeneron-prevail-in-european-patent-dispute-amgen-over-cholesterol-drugs